Fios Genomics is a SME that provides an extensive range of data analysis services to Pharma, CROs and academia for drug discovery and development and applied research across all species. FIOS provides access to a combined resource of in-house bioinformaticians, statisticians and biologists working together to analyse and interpret genomic, transcriptomic, proteomic and metabolomic data. FIOS specialises in the analysis of high dimensional, multi-variant datasets and recognizing patterns and trends associated with a trait, disease or drug response. Using robust statistics and pathway analysis, the team provides analysis services of a deeper and wider scope to traditional methods. FIOS’ proprietary computer solutions allow the analysis of large datasets to be parallelised saving processing time and avoiding the complications that can arise when analysing data in batches.
- Dr Sarah Lynagh is Chief Executive Officer at FIOS. She holds a PhD in Neuropharmacology from the University of Glasgow, has over 10 years’ experience in drug development and commercialization within CROs and is a member of the Industrial Advisory Board in the Department of Informatics at King’s College, London. She will lead and coordinate FIOS research activities for VISICORT.
- Dr Max Bylesjö is Technical Director at FIOS. His previous roles included team leader at Almac Diagnostics, Northern Ireland and Senior Bioinformatician at Sistemic, Scotland. In his current and previous positions, Dr Bylesjo has been line manager for PhD-level scientists and has been involved in mentoring of junior scientists. Dr Bylesjo has a proven track record in bioinformatics research for “omics” data analysis and integration and has published regularly in the area. His doctoral thesis was based on developing methods for the analysis and integration of omics data sets and was conducted in Department of Chemistry, Umeå University, Sweden.